mRNA-based therapeutics — developing a new class of drugs

By Ugur Sahin, K. Karikó, Ö. Türeci. Nature reviews. Drug discovery, 2014

2,098 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. (2019, positive): “Since the first pre-clinical studies in the 1990s,(1) significant progress in the clinical translation of mRNA therapeutics has been made through advances in the design of mRNA manufacturing and intracellular delivery methods.(2) The translatability and stability of mRNA as well as its immunostimula”
mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, methodology): “CONCLUSION AND PROSPECTS mRNA-based therapeutics have made great strides, achieving remarkable improvement in mRNA stability, function, and production during the past 30 years.(2) mRNA drugs exploit cells as factories for antigen or functional protein production with promising efficacy and sufficien”
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability (2021, positive): “Importantly, this illustrates that optimization of only the mRNA structure is not sufficient for creating effective mRNA vaccines: additional protection and delivery systems are needed (Kauffman et al., 2016; Sahin et al., 2014).”
Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine (2020, background): “It is molecularly well defined, free of animal-origin materials and synthesized by an efficient, cell-free in vitro transcription process from DNA templates 4,8,9 .”